GlassScriptPhysician profile
Nihad Muhrez
NPI 1528098506
$270,804.56
in general payments reported to CMS, 2019-2025
47 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $32K · 2021: $40K · 2022: $52K · 2023: $35K · 2024: $25K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Food and Beverage: $8,825 · Travel and Lodging: $2,798 · Education: $88.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,750.00 |
| Food and Beverage | $8,824.67 |
| Travel and Lodging | $2,797.99 |
| Education | $88.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $214,035.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28,230.82 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $16,049.32 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $1,699.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic Minimed, INC. | $1,539.86 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $1,054.63 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $808.18 | 2019-2023 | Steglujan, Steglatro, Segluromet |
| Dexcom, INC. | $712.29 | 2019-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $614.97 | 2023-2025 | Korlym |
| Abbvie INC. | $604.30 | 2019-2025 | |
| Insulet Corporation | $586.36 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $563.44 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Ibsa Pharma INC. | $423.32 | 2019-2025 | Tirosint, Licart, Flector |
| Bayer Healthcare Pharmaceuticals INC. | $371.22 | 2021-2025 | |
| Amgen INC. | $367.84 | 2021-2025 | Tepezza, Evenity, Prolia |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $322.09 | 2019-2025 | Unithroid |
| Becton, Dickinson and Company | $306.63 | 2019-2020 | |
| Abbott Laboratories | $279.90 | 2019-2024 | Proclaim, Freestyle Libre 3, Eterna |
| Medtronic, INC. | $245.07 | 2021-2025 | Inpen Smart Insulin Delivery System |
| Shire North American Group INC | $213.22 | 2019 | |
| Recordati_rare_diseases_inc. | $175.58 | 2025 | Isturisa |
| Antares Pharma, INC. | $157.27 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Roche Diabetes Care, INC. | $145.52 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $134.34 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Pharmaceuticals, INC | $134.31 | 2019-2020 | |
| Clarus Therapeutics INC. | $104.79 | 2021 | |
| Ascendis Pharma Endocrinology INC | $98.38 | 2023-2025 | Yorvipath |
| Beta Bionics, INC. | $88.27 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Embecta Corp. | $80.97 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Avvisto Therapeutics, LLC | $74.97 | 2024-2025 | Cycloset |
| Halozyme INC | $62.54 | 2023 | |
| Eisai INC. | $61.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $57.16 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $55.12 | 2025 | Strensiq |
| Valeritas, INC. | $50.87 | 2019 | |
| Ascensia Diabetes Care US INC. | $49.83 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $30.56 | 2023 | Adthyza |
| Sequel Med Tech, LLC | $25.74 | 2025 | Twiist |
| Astellas Pharma US INC | $24.54 | 2023 | Veozah |
| Roche Diagnostics Corporation | $24.47 | 2020 | |
| Glaxosmithkline, LLC. | $23.21 | 2025 | Shingrix |
| Horizon Therapeutics Plc | $21.87 | 2022 | |
| Acella Pharmaceuticals, LLC | $20.67 | 2024 | NP Thyroid 60 |
| Theracosbio, LLC | $19.69 | 2024 | Brenzavvy |
| Companion Medical, INC. | $18.73 | 2019 | |
| Vivus LLC | $18.33 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nihad Muhrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.